Archives of Pharmacal Research

, Volume 27, Issue 1, pp 13–18 | Cite as

Some pyridazinone and phthalazinone derivatives and their vasodilator activities

  • Seref Demirayak
  • Ahmet Cagri Karaburun
  • Ismail Kayagil
  • Kevser Erol
  • Basar Sirmagul
Research Articles Articles


In this study, 6-[(4-arylidene-2-phenyl-5-oxoimidazolin-1-yl)phenyl]-4,5-dihydro-3(2H)-pyridazinone and 4-[(4-arylidene-2-phenyl-5-oxoimidazolin-1-yl)phenyl]-1(2H)-phthalazinone derivatives were synthesized by reacting 6-(4-aminophenyl)-4,5-dihydro-3(2H)-pyridazinone or 4-(4-aminophenyl)-1(2H)-phthalazinone compound with different 4-arylidene-2-phenyl-5(4H)-oxazolone derivatives. The vasodilator activities of the compounds were examined bothin vitro andin vivo. Some pyridazinone derivatives showed appreciable activity.

Key words

Pyridazinone Phthalazinone Vasodilator activity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Betti, L., Floridi, M., Giannaccini, G., Manetti, F., Strappaghetti, G., Tafi, A., and Botta, M., α1-Adrenoceptor antagonists. 5. Pyridazinone-arylpiperazines. Probing the influence on affinity and selectivity of bothortho-Alkoxy groups at the arylpiperazine moiety and cyclic substituents at the pyridazinone nucleus.Bioorg. Med. Chem. Lett., 13, 171–173 (2003).PubMedCrossRefGoogle Scholar
  2. Cignarella, G., Barlocco, D., Pinna, G. A., Loriga, M., Curzu, M., Tofanetti, O., Germini, M., Cazzulani, P., and Cavalletti, E., Synthesis and biological evaluations of substituted benzo[h]-cinnolinones and 3-benzo[6,7]cyclohepta[1,2-c]pyridazinones: higher homologues of the antihypertensive and antithrombotic 5H-indeno[1,2-c]pyridazinones.J. Med. Chem., 32, 2277–2282 (1989).PubMedCrossRefGoogle Scholar
  3. Combs, D. W., Rampulla, M. S., Bell, S. C., Klaubert, D. H., Tobia, A. J., Falotico, R., Haertlein, B., Lakas-Weiss, C., and Moore, J. B., 6-Benzoxazinylpyridazin-3-ones, Potent, longacting positive inotrope and peripheral vasodilator agents.J. Med. Chem., 33, 380–386 (1990).PubMedCrossRefGoogle Scholar
  4. Corsano, S., Vezza, R., Scapicchi, R., Foresi, S., Strappaghetti, G., Nenci, G. G., and Gresele, P., New pyridazinone derivatives as inhibitors of platelet aggregation.Eur. J. Med. Chem., 30, 627–631 (1995).CrossRefGoogle Scholar
  5. Curran, W. V. and Ross, A., 6-Phenyl-4,5-dihydro-3-(2H)-pyridazinones, A series of hypotensive agents.J. Med. Chem., 17, 273–281 (1974).PubMedCrossRefGoogle Scholar
  6. Demirayak, S., Benkli, K., Karaburun, A. C., Erol, K., and Boydag, S., Some 1-substituted 3-aryl-1,4-dihydro-1,2,4-triazino[4,3-a]benzimidazoles and their vasodilatory activities.Farmaco, 52, 741–744 (1997).PubMedGoogle Scholar
  7. Foye, W. O., Lemke, T. L., and Williams, D. A.,Principles of Medicinal Chemistry, 4th Ed., Williams and Wilkins. London, 345–387, 499–534 (1995).Google Scholar
  8. Haikala, H. O., Honkanen, E. J., Lonnberg, K. K., Nore, P. T., Pystynen, J. J., Luiro, A. M., and Pippuri, A. K., Preparation of arylazinones for treatment of congestive heart failure, Brit. UK Pat. Appl., EP 597,540. C.A. 121, 114, 228967 (1997).Google Scholar
  9. Heinisch, G. and Kopelent-Frank, H., Pharmacologically active pyridazine derivatives, Part II.Prog. Med. Chem., 29, 141–183 (1992).PubMedCrossRefGoogle Scholar
  10. Laguna, R., Rodriguez-Linarez, B., Cano, E., Estevez, I., Ravina, E., and Sotelo, E., Pyridazines. XIII. Synthesis of 6-aryl-5-oxygenated substituted-3(2H)-pyridazinones and evaluation as platelet aggregation inhibitors.Chem. Pharm. Bull., 45, 1151–1155 (1997).PubMedGoogle Scholar
  11. McEvoy, F. J. and Allen, Jr. G. R., 6-(Substituted phenyl)-5-substituted-4,5-dihydro-3(2H)-pyridazinones.J. Med. Chem., 17, 281–286 (1974).PubMedCrossRefGoogle Scholar
  12. Montero-Lastres, A., Fraiz, N., Laguna, R., Cano, E., Esteves, I., and Ravina, E. Pyridazines XVIII. 6-aryl-3(2H)-pyridazinones inhibit calcium influx in stimulated platelets.Biol. Pharm. Bull., 22, 1376–1379 (1999).PubMedGoogle Scholar
  13. Seki, T., Nakao, T., Masuda, T., Hasumi, K., Gotanda, K., Ishimori, T., Honma, S., Minami, N., Shibata, K., and Yasuda, K., Studies on agents with vasodilator and β-blocking activities. IV,Chem. Pharm. Bull., 44, 2061–2069 (1996).PubMedGoogle Scholar
  14. Sircar, I., Weishaar, R. E., Kobylarz, D., Moos, W. H., and Bristol, J. A., Cardiotonic agents, 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H)-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds, Structure-activity relationships and correlation within vivo positive inotropic activity.J. Med. Chem., 30, 1955–1962 (1987).PubMedCrossRefGoogle Scholar
  15. Sotelo, E., Fraiz, N., Yanez, M., Terrades, V., Laguna, R., Cano, E., and Ravina, E. Pyridazines. Part XXIX: Synthesis and platelet aggregation inhibition activity of 5-substituted-6-phenyl-3(2H)-pyridazinones. Novel aspects of their biological actions.Bioorg. Med. Chem., 10, 2873–2882 (2002).PubMedCrossRefGoogle Scholar
  16. Sotelo, E., Fraiz, N., Yanez, M. R. Laguna, E. Cano, and E. Ravina, Pyridazines. Part 31: Synthesis and antiplatelet activity of 4,5-disubstituted-6-phenyl-3(2H)-pyridazinones.Chem. Pharm. Bull., 50, 1574–1577 (2002).PubMedCrossRefGoogle Scholar
  17. Szasz, G. and Budvavi-Bavauy, Z.,Pharmaceutical Chemistry of Antihypertensive Agents, CRC Press, Boca Raton, 3–265 (1991).Google Scholar
  18. Thyes, M., Lehmann, H. D., Gries, J., König, H., Kretzschmar, R., Kunze, J., Lebkucher, R., and Lenke, D., 6-Phenyl-4,5-dihydro-3-(2H)-pyridazinones.J. Med. Chem., 26, 800–807 (1983).PubMedCrossRefGoogle Scholar
  19. Tishler, M. and Stanovnik, B., Pyridazines.Adv. Heterocyclic Chem., 9, 121 (1968).Google Scholar
  20. Tishler, M. and Stanovnik, B., Recent advances in pyridazine chemistry.Adv. Heterocyclic Chem., 24, 363 (1979).CrossRefGoogle Scholar
  21. Tishler, M. and Stanovnik, B., Advances in pyridazine chemistry.Adv. Heterocyclic Chem., 49, 385 (1990).CrossRefGoogle Scholar
  22. Turcki, I. J., Ed.,The Chemistry of Heterocyclic Compounds, Oxazoles, An Intersciences Pub., John Wiley and Sons, p. 361–729 (1986).Google Scholar
  23. Van der Mey, M., Boss, H., Couwenberg, D., Hatzelmann, A., Sterk, G. J., Goubitz, K., Schenk, H., and Timmerman, H., Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity ofcis-tetra- andcis-hexahydrophthalazinones.J. Med. Chem., 45, 2526–2533 (2002).PubMedCrossRefGoogle Scholar
  24. Wolf, M. E., Burger’s Medicinal Chemistry And Drug Discovery 5 th ed. Vol. 2, p. 152–462. John Wiley and Sons, New York (1997).Google Scholar
  25. Yamaguchi, M., Kamei, K., Koga, T., Akima, M., Maruyama, A., Kurokki, T., and Ohi, N., Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones.J. Med. Chem., 36, 4061–4068 (1993).PubMedCrossRefGoogle Scholar
  26. Zwieten, P. A. V. and Greenlee, W. J.,Antihypertensive drugs, Harwood Academic Publishers, p. 1–528 (1997).Google Scholar

Copyright information

© The Pharmaceutical Society of Korea 2004

Authors and Affiliations

  • Seref Demirayak
    • 1
  • Ahmet Cagri Karaburun
    • 1
  • Ismail Kayagil
    • 1
  • Kevser Erol
    • 2
  • Basar Sirmagul
    • 2
  1. 1.Dept. of Pharmaceutical Chemistry, Faculty of PharmacyUniversity of AnadoluEskisehirTurkey
  2. 2.Dept. of Pharmacology, Faculty of MedicineUniversity of OsmangaziEskisehirTurkey

Personalised recommendations